- The French VICAN2 cohort study finds 5 unique trajectories for adherence to adjuvant endocrine therapy (AET) in patients with nonmetastatic, hormone receptor (HR)-positive breast cancer.
- Not receiving chemotherapy and lacking a personalized care plan are associated with the 2 worst trajectories.
Why this matters
- Clinicians have a new way to categorize adherence to AET and identify risk and protective factors.
- Retrospective cohort study of women (n=674) from initiation to cessation of the 5-year period for AET for HR+ breast cancer, using an administrative database.
- Trajectories were identified by group-based trajectory modeling.
- Funding: French National Institute of Cancer; others.
- Newly identified adherence trajectories and their prevalence:
- Quick decline and stop (by end of 2nd year): 5.2%.
- Moderate decline and stop (by end of 4th year): 6.4%.
- Slow decline: 17.2%.
- High adherence (AET taken >80% to 95% of the time): 30.0%.
- Maintenance of very high adherence (AET taken >95% of the time): 41.2%.
- Risk factors for fitting into the worst 2 adherence categories:
- Did not receive chemotherapy (vs received chemotherapy): adjusted OR (aOR), 2.07 (95% CI, 1.19-3.63); and
- Lack of a personalized care plan (vs have a care plan): aOR, 1.69 (95% CI, 1.01-2.83).
- Observational design.